10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the...read more
Nanobiotix, a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy, raised $99 million by offering 7.3 million ADS equivalents at $13.50, the low end of the range of $13.50 to $14.50. The company offered 0.8 million more ADS...read more
Nanobiotix, a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy, set the range for its upcoming IPO on Wednesday.
The Paris, France-based company now plans to raise $91 million by offering 6.5 million shares at a price range...read more
Nanobiotix, a commercial-stage French biotech developing nanoparticle therapies for cancer, announced terms for its IPO on Monday.
The Paris, France-based company plans to raise $95 million by offering 6.5 million ADS equivalents at $14.69, the as-converted...read more
US IPO Weekly Recap: Airbnb and DoorDash make their public debuts in a 10 IPO week
10 IPOs entered the public market this past week headlined by Airbnb (ABNB) and DoorDash (DASH), which completed the largest and second-largest IPOs of 2020, respectively. They were joined by 20 blank check IPOs in the...read more
French drug developer Nanobiotix prices upsized $99 million US IPO at $13.50 low end
Nanobiotix, a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy, raised $99 million by offering 7.3 million ADS equivalents at $13.50, the low end of the range of $13.50 to $14.50. The company offered 0.8 million more ADS...read more
French drug developer Nanobiotix sets range at $13.50 to $14.50 ahead of $91 million US IPO
Nanobiotix, a late-stage French developer of nanoparticle drugs that improve cancer radiotherapy, set the range for its upcoming IPO on Wednesday. The Paris, France-based company now plans to raise $91 million by offering 6.5 million shares at a price range...read more
Commercial-stage oncology biotech Nanobiotix sets terms for $95 million US IPO
Nanobiotix, a commercial-stage French biotech developing nanoparticle therapies for cancer, announced terms for its IPO on Monday. The Paris, France-based company plans to raise $95 million by offering 6.5 million ADS equivalents at $14.69, the as-converted...read more